Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab (GMAB) to $37 from $50 and keeps a Buy rating on the ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

The scientists trying to find a cure for cancer know they have to be patient. Likewise, most shareholders who back companies ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

In a recent filing with the U.S. Securities and Exchange Commission, Danish biotech company Genmab (NASDAQ:GMAB) A/S (current market cap: $11.44 billion) has reported transactions as part of its ...

Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have been given an average rating of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat.com reports.

Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...